Cargando…

(68)Ga and (188)Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies

PURPOSE: This work aims to develop, validate and optimize the radiolabeling of Starch-Based Microparticles (SBMP) by (188)Re and (68)Ga in the form of ready-to-use radiolabeling kits, the ultimate goal being to obtain a unique theranostic vector for the treatment of Hepatocellular Carcinoma. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Verger, Elise, Drion, Pierre, Meffre, Geneviève, Bernard, Claire, Duwez, Luc, Lepareur, Nicolas, Couturier, Olivier, Hindré, François, Hustinx, Roland, Lacoeuille, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065223/
https://www.ncbi.nlm.nih.gov/pubmed/27741267
http://dx.doi.org/10.1371/journal.pone.0164626
Descripción
Sumario:PURPOSE: This work aims to develop, validate and optimize the radiolabeling of Starch-Based Microparticles (SBMP) by (188)Re and (68)Ga in the form of ready-to-use radiolabeling kits, the ultimate goal being to obtain a unique theranostic vector for the treatment of Hepatocellular Carcinoma. METHODS: Optimal labeling conditions and composition of freeze-dried kits were defined by monitoring the radiochemical purity while varying several parameters. In vitro stability studies were carried out, as well as an in vivo biodistribution as a preliminary approach with the intra-arterial injection of (68)Ga radiolabeled SBMP into the hepatic artery of DENA-induced rats followed by PET/CT imaging. RESULTS: Kits were optimized for (188)Re and (68)Ga with high and stable radiochemical purity (>95% and >98% respectively). The in vivo preliminary study was successful with more than 95% of activity found in the liver and mostly in the tumorous part. CONCLUSION: SBMP are a promising theranostic agent for the Selective Internal Radiation Therapy of Hepatocellular carcinoma.